Impact of proactive of infliximab monitoring using the Bayesian approach in the maintenance phase in patients with inflammatory bowel disease

Gastroenterol Hepatol. 2023 Aug-Sep;46(7):504-511. doi: 10.1016/j.gastrohep.2022.10.019. Epub 2022 Nov 15.
[Article in English, Spanish]

Abstract

Background and objectives: There is increasing evidence that proactive monitoring is useful in improving the control of inflammatory bowel disease, although it remains controversial. The aim of this study was to evaluate the efficacy of proactive TDM based on the Bayesian approach to optimise the IFX dose compared with the standard of care dosing in patients with IBD.

Methods: Retrospective observational cohort of inflammatory bowel disease patients>18 years. Patients were classified into two groups according to the strategy used to optimise the dose of IFX: a standard therapy group (ST-group) with clinically based dose adjustment and therapeutic drug monitoring group (TDM-group), with estimation of pharmacokinetic parameters calculated by Bayesian prediction.

Results: A total of 153 patients were included. Of these, 75 were in the TDM-group. Clinical response at week 52 was evaluated in 114 patients. The proportion of patients who achieved clinical remission was higher in the TDM than in the ST-group (80.7% vs 61.4%, respectively, p=0.023). A total of 28 patients (24.6%) met the parameters for the composite variable 'poor clinical outcome' at week 52. The proportion of patients who reached this outcome was lower in the TDM-group than in the ST-group (12.3% vs 36.8%, respectively, p=0.002).

Conclusions: Proactive therapeutic drug monitoring using Bayesian approach is associated with higher secondary response and fewer long-term complications.

Keywords: Enfermedad inflamatoria intestinal; Inflammatory bowel disease; Infliximab; Maintenance; Mantenimiento; Monitorización farmacocinética; Proactive; Proactivo; Therapeutic drug monitoring.

MeSH terms

  • Bayes Theorem
  • Drug Monitoring
  • Gastrointestinal Agents* / therapeutic use
  • Humans
  • Inflammatory Bowel Diseases* / drug therapy
  • Infliximab / therapeutic use
  • Retrospective Studies

Substances

  • Infliximab
  • Gastrointestinal Agents